Home > Compound List > Product Information
Clemastine_Molecular_structure_CAS_15686-51-8)
Click picture or here to close

Clemastine

Catalog No. DB00283 Name DrugBank
CAS Number 15686-51-8 Website http://www.ualberta.ca/
M. F. C21H26ClNO Telephone (780) 492-3111
M. W. 343.89024 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 168

SYNONYMS

IUPAC name
(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine
IUPAC Traditional name
clemastine
Brand Name
Meclastin
Mecloprodin
Tavist
Tavist-1
Synonyms
Clemastinum [INN-Latin]
Clemastine Fumarate
Clemastina [INN-Spanish]

DATABASE IDS

PubChem SID 46506492
PubChem CID 26987
CAS Number 15686-51-8

PROPERTIES

Hydrophobicity(logP) 5.2
Solubility Soluble (hydrogen fumarate formulation)

DETAILS

Description (English)
Item Information
Drug Groups approved
Description An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. [PubChem]
Indication For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.
Pharmacology Clemastine is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the "flare" and "itch" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1- receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1- receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1- receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine.
Toxicity Oral LD50 in rat and mouse is 3550 mg/kg and 730 mg/kg, respectively. Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include excitement, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio-respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common.
Affected Organisms
Humans and other mammals
Biotransformation Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation.
Absorption Rapidly absorbed from the gastrointestinal tract.
Elimination Urinary excretion is the major mode of elimination.
References
Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17. [Pubmed]
Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17. Pubmed
  • Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. Pubmed